
कृपया अन्य खोज का प्रयास करें
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops AB569 for treating antibiotic-resistant bacterial infections and as a topical treatment for wounds; and Borg, a peptide-solid surface interface, which are binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Arch Biopartners Inc. is based in Toronto, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Daniel Abraham Muruve | - | 2011 | Co-Founder, Chief Science Officer & Member of Scientific Advisory Board |
Hindrik Mulder | - | - | Member of Scientific Advisory Board |
Richard Rossman | 80 | 2010 | Independent Director |
Claude Allary | 70 | 2012 | Independent Director |
Richard Gabriel Muruve | 54 | 2005 | Co-Founder, CEO, President & Director |
Robert Hodges | - | - | Member of Scientific Advisory Board |
Andrew Bishop | 59 | 2010 | CFO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है